aMAP risk score predicts hepatocellular carcinoma development in patients with chronic hepatitis

Rong Fan; George Papatheodoridis; Jian Sun; Hamish Innes; Hidenori Toyoda; Qing Xie; Shuyuan Mo; Vana Sypsa; Indra Neil Guha; Takashi Kumada; Junqi Niu; George Dalekos; Satoshi Yasuda; Eleanor Barnes; Jianqi Lian; Vithika Suri; Ramazan Idilman; Stephen T. Barclay; Xiaoguang Dou; Thomas Berg; Peter C. Hayes; John F. Flaherty; Yuanping Zhou; Zhengang Zhang; Maria Buti; Sharon J. Hutchinson; Yabing Guo; Jose Luis Calleja; Lanjia Lin; Longfeng Zhao; Yongpeng Chen; Harry LA. Janssen; Chaonan Zhu; Lei Shi; Xiaoping Tang; Anuj Gaggar; Lai Wei; Jidong Jia; William L. Irving; Philip J. Johnson; Pietro Lampertico; Jinlin Hou

doi:10.1016/j.jhep.2020.07.025

aMAP risk score predicts hepatocellular carcinoma development in patients with chronic hepatitis

Rong Fan, George Papatheodoridis, Jian Sun, Hamish Innes, Hidenori Toyoda, Qing Xie, Shuyuan Mo, Vana Sypsa , Indra Neil Guha, Takashi Kumada, Junqi Niu, George Dalekos, Satoshi Yasuda, Eleanor Barnes, Jianqi Lian, Vithika Suri, Ramazan Idilman, Stephen T. Barclay, Xiaoguang Dou, Thomas BergPeter C. Hayes, John F. Flaherty, Yuanping Zhou, Zhengang Zhang, Maria Buti, Sharon J. Hutchinson, Yabing Guo, Jose Luis Calleja, Lanjia Lin, Longfeng Zhao, Yongpeng Chen, Harry LA. Janssen, Chaonan Zhu, Lei Shi, Xiaoping Tang, Anuj Gaggar, Lai Wei, Jidong Jia, William L. Irving, Philip J. Johnson^*, Pietro Lampertico^*, Jinlin Hou^*

^*Corresponding author for this work

SHLS School Office

Research output: Contribution to journal › Article

Abstract

Background & AimsHepatocellular carcinoma (HCC) is the leading cause of death in patients with chronichepatitis. In this international collaboration, we sought to develop a global universal HCCrisk score to predict the HCC development for chronic hepatitis patients.
MethodsA total of 17,374 patients, comprising 10,578 treated Asian chronic hepatitis B (CHB)patients, 2510 treated Caucasian CHB patients, 3566 treated hepatitis C virus(HCV)-infected patients (including 2489 patients with cirrhosis achieving a sustainedvirologic response) and 720 non-viral hepatitis (NVH) patients from 11 internationalprospective observational cohorts or randomized controlled trials, were divided into atraining cohort (3688 Asian CHB patients) and 9 validation cohorts with differentaetiologies and ethnicities (N =13,686).
ResultsWe developed an HCC risk score, called the aMAP score (ranging from 0 to 100), thatinvolves only age, Male, Albumin-bilirubin and Platelets. This metric performedexcellently in assessing HCC risk not only in patients with hepatitis of differentaetiologies but also in those with different ethnicities (c-index: 0.82-0.87). Cut-off valuesof 50 and 60 were best for discriminating HCC risk. The 3- or 5-year cumulativeincidences of HCC were 0-0.8%, 1.5-4.8%, and 8.1-19.9% in the low- (N=7413, 43.6%),medium- (N=6529, 38.4%), and high-risk (N =3044, 17.9%) groups, respectively. Thecut-off value of 50 was associated with a sensitivity of 85.7-100% and a negativepredictive value of 99.3-100%. The cut-off value of 60 resulted in a specificity of56.6-95.8% and a positive predictive value of 6.6-15.7%.
ConclusionsThis objective, simple, reliable risk score based on five common parameters accuratelypredicts HCC development, regardless of aetiology and ethnicity, which may help toestablish a risk score-guided HCC surveillance strategy worldwide.

Original language	English
Number of pages	47
Journal	Journal of Hepatology
DOIs	https://doi.org/10.1016/j.jhep.2020.07.025
Publication status	Published - 20 Jul 2020

Keywords

hepatocellular carcinoma; risk score; hepatitis B virus; hepatitis C virus; non-alcoholic fatty liver disease

Documents and Links

10.1016/j.jhep.2020.07.025

Embargoed Document

Fan, R. et al (2020) aMAP risk score predicts hepatocellular carcinoma development in patients with chronic hepatitisin chronic hepatitis patients an international cohort collaboration
Accepted author manuscript, 2.36 MB

Fingerprint Dive into the research topics of 'aMAP risk score predicts hepatocellular carcinoma development in patients with chronic hepatitis'. Together they form a unique fingerprint.

Cite this

Fan, R., Papatheodoridis, G., Sun, J., Innes, H., Toyoda, H., Xie, Q., Mo, S., Sypsa , V., Guha, I. N., Kumada, T., Niu, J., Dalekos, G., Yasuda, S., Barnes, E., Lian, J., Suri, V., Idilman, R., Barclay, S. T., Dou, X., ... Hou, J. (2020). aMAP risk score predicts hepatocellular carcinoma development in patients with chronic hepatitis. Journal of Hepatology. https://doi.org/10.1016/j.jhep.2020.07.025

Fan, Rong ; Papatheodoridis, George ; Sun, Jian ; Innes, Hamish ; Toyoda, Hidenori ; Xie, Qing ; Mo, Shuyuan ; Sypsa , Vana ; Guha, Indra Neil ; Kumada, Takashi ; Niu, Junqi ; Dalekos, George ; Yasuda, Satoshi ; Barnes, Eleanor ; Lian, Jianqi ; Suri, Vithika ; Idilman, Ramazan ; Barclay, Stephen T. ; Dou, Xiaoguang ; Berg, Thomas ; Hayes, Peter C. ; Flaherty, John F. ; Zhou, Yuanping ; Zhang, Zhengang ; Buti, Maria ; Hutchinson, Sharon J. ; Guo, Yabing ; Calleja, Jose Luis ; Lin, Lanjia ; Zhao, Longfeng ; Chen, Yongpeng ; Janssen, Harry LA. ; Zhu, Chaonan ; Shi, Lei ; Tang, Xiaoping ; Gaggar, Anuj ; Wei, Lai ; Jia, Jidong ; Irving, William L. ; Johnson, Philip J. ; Lampertico, Pietro ; Hou, Jinlin. / aMAP risk score predicts hepatocellular carcinoma development in patients with chronic hepatitis. In: Journal of Hepatology. 2020.

@article{e3bf5dc2118d4d8ea37d6b7447f0adff,

title = "aMAP risk score predicts hepatocellular carcinoma development in patients with chronic hepatitis",

abstract = "Background & AimsHepatocellular carcinoma (HCC) is the leading cause of death in patients with chronichepatitis. In this international collaboration, we sought to develop a global universal HCCrisk score to predict the HCC development for chronic hepatitis patients.MethodsA total of 17,374 patients, comprising 10,578 treated Asian chronic hepatitis B (CHB)patients, 2510 treated Caucasian CHB patients, 3566 treated hepatitis C virus(HCV)-infected patients (including 2489 patients with cirrhosis achieving a sustainedvirologic response) and 720 non-viral hepatitis (NVH) patients from 11 internationalprospective observational cohorts or randomized controlled trials, were divided into atraining cohort (3688 Asian CHB patients) and 9 validation cohorts with differentaetiologies and ethnicities (N =13,686).ResultsWe developed an HCC risk score, called the aMAP score (ranging from 0 to 100), thatinvolves only age, Male, Albumin-bilirubin and Platelets. This metric performedexcellently in assessing HCC risk not only in patients with hepatitis of differentaetiologies but also in those with different ethnicities (c-index: 0.82-0.87). Cut-off valuesof 50 and 60 were best for discriminating HCC risk. The 3- or 5-year cumulativeincidences of HCC were 0-0.8%, 1.5-4.8%, and 8.1-19.9% in the low- (N=7413, 43.6%),medium- (N=6529, 38.4%), and high-risk (N =3044, 17.9%) groups, respectively. Thecut-off value of 50 was associated with a sensitivity of 85.7-100% and a negativepredictive value of 99.3-100%. The cut-off value of 60 resulted in a specificity of56.6-95.8% and a positive predictive value of 6.6-15.7%.ConclusionsThis objective, simple, reliable risk score based on five common parameters accuratelypredicts HCC development, regardless of aetiology and ethnicity, which may help toestablish a risk score-guided HCC surveillance strategy worldwide. ",

keywords = "hepatocellular carcinoma; risk score; hepatitis B virus; hepatitis C virus; non-alcoholic fatty liver disease",

author = "Rong Fan and George Papatheodoridis and Jian Sun and Hamish Innes and Hidenori Toyoda and Qing Xie and Shuyuan Mo and Vana Sypsa and Guha, {Indra Neil} and Takashi Kumada and Junqi Niu and George Dalekos and Satoshi Yasuda and Eleanor Barnes and Jianqi Lian and Vithika Suri and Ramazan Idilman and Barclay, {Stephen T.} and Xiaoguang Dou and Thomas Berg and Hayes, {Peter C.} and Flaherty, {John F.} and Yuanping Zhou and Zhengang Zhang and Maria Buti and Hutchinson, {Sharon J.} and Yabing Guo and Calleja, {Jose Luis} and Lanjia Lin and Longfeng Zhao and Yongpeng Chen and Janssen, {Harry LA.} and Chaonan Zhu and Lei Shi and Xiaoping Tang and Anuj Gaggar and Lai Wei and Jidong Jia and Irving, {William L.} and Johnson, {Philip J.} and Pietro Lampertico and Jinlin Hou",

note = "*1-1-70* Due to be published OA (from publisher website) but only early version available at time of checking 28/07/20 ST - check the pub date - upload the VoR AAM: not yet made open as full OA info not yet available. ET 29/7/20 Acceptance from webpage",

year = "2020",

month = jul,

day = "20",

doi = "10.1016/j.jhep.2020.07.025",

language = "English",

journal = "Journal of Hepatology",

issn = "0168-8278",

publisher = "Elsevier B.V.",

}

Fan, R, Papatheodoridis, G, Sun, J, Innes, H, Toyoda, H, Xie, Q, Mo, S, Sypsa , V, Guha, IN, Kumada, T, Niu, J, Dalekos, G, Yasuda, S, Barnes, E, Lian, J, Suri, V, Idilman, R, Barclay, ST, Dou, X, Berg, T, Hayes, PC, Flaherty, JF, Zhou, Y, Zhang, Z, Buti, M, Hutchinson, SJ, Guo, Y, Calleja, JL, Lin, L, Zhao, L, Chen, Y, Janssen, HLA, Zhu, C, Shi, L, Tang, X, Gaggar, A, Wei, L, Jia, J, Irving, WL, Johnson, PJ, Lampertico, P & Hou, J 2020, 'aMAP risk score predicts hepatocellular carcinoma development in patients with chronic hepatitis', Journal of Hepatology. https://doi.org/10.1016/j.jhep.2020.07.025

aMAP risk score predicts hepatocellular carcinoma development in patients with chronic hepatitis. / Fan, Rong; Papatheodoridis, George; Sun, Jian; Innes, Hamish; Toyoda, Hidenori; Xie, Qing; Mo, Shuyuan; Sypsa , Vana; Guha, Indra Neil; Kumada, Takashi; Niu, Junqi; Dalekos, George; Yasuda, Satoshi; Barnes, Eleanor; Lian, Jianqi; Suri, Vithika; Idilman, Ramazan; Barclay, Stephen T.; Dou, Xiaoguang; Berg, Thomas; Hayes, Peter C.; Flaherty, John F.; Zhou, Yuanping; Zhang, Zhengang; Buti, Maria; Hutchinson, Sharon J.; Guo, Yabing; Calleja, Jose Luis; Lin, Lanjia; Zhao, Longfeng; Chen, Yongpeng; Janssen, Harry LA.; Zhu, Chaonan; Shi, Lei; Tang, Xiaoping; Gaggar, Anuj; Wei, Lai; Jia, Jidong; Irving, William L.; Johnson, Philip J.; Lampertico, Pietro; Hou, Jinlin.

In: Journal of Hepatology, 20.07.2020.

Research output: Contribution to journal › Article

TY - JOUR

T1 - aMAP risk score predicts hepatocellular carcinoma development in patients with chronic hepatitis

AU - Fan, Rong

AU - Papatheodoridis, George

AU - Sun, Jian

AU - Innes, Hamish

AU - Toyoda, Hidenori

AU - Xie, Qing

AU - Mo, Shuyuan

AU - Sypsa , Vana

AU - Guha, Indra Neil

AU - Kumada, Takashi

AU - Niu, Junqi

AU - Dalekos, George

AU - Yasuda, Satoshi

AU - Barnes, Eleanor

AU - Lian, Jianqi

AU - Suri, Vithika

AU - Idilman, Ramazan

AU - Barclay, Stephen T.

AU - Dou, Xiaoguang

AU - Berg, Thomas

AU - Hayes, Peter C.

AU - Flaherty, John F.

AU - Zhou, Yuanping

AU - Zhang, Zhengang

AU - Buti, Maria

AU - Hutchinson, Sharon J.

AU - Guo, Yabing

AU - Calleja, Jose Luis

AU - Lin, Lanjia

AU - Zhao, Longfeng

AU - Chen, Yongpeng

AU - Janssen, Harry LA.

AU - Zhu, Chaonan

AU - Shi, Lei

AU - Tang, Xiaoping

AU - Gaggar, Anuj

AU - Wei, Lai

AU - Jia, Jidong

AU - Irving, William L.

AU - Johnson, Philip J.

AU - Lampertico, Pietro

AU - Hou, Jinlin

N1 - *1-1-70* Due to be published OA (from publisher website) but only early version available at time of checking 28/07/20 ST - check the pub date - upload the VoR AAM: not yet made open as full OA info not yet available. ET 29/7/20 Acceptance from webpage

PY - 2020/7/20

Y1 - 2020/7/20

N2 - Background & AimsHepatocellular carcinoma (HCC) is the leading cause of death in patients with chronichepatitis. In this international collaboration, we sought to develop a global universal HCCrisk score to predict the HCC development for chronic hepatitis patients.MethodsA total of 17,374 patients, comprising 10,578 treated Asian chronic hepatitis B (CHB)patients, 2510 treated Caucasian CHB patients, 3566 treated hepatitis C virus(HCV)-infected patients (including 2489 patients with cirrhosis achieving a sustainedvirologic response) and 720 non-viral hepatitis (NVH) patients from 11 internationalprospective observational cohorts or randomized controlled trials, were divided into atraining cohort (3688 Asian CHB patients) and 9 validation cohorts with differentaetiologies and ethnicities (N =13,686).ResultsWe developed an HCC risk score, called the aMAP score (ranging from 0 to 100), thatinvolves only age, Male, Albumin-bilirubin and Platelets. This metric performedexcellently in assessing HCC risk not only in patients with hepatitis of differentaetiologies but also in those with different ethnicities (c-index: 0.82-0.87). Cut-off valuesof 50 and 60 were best for discriminating HCC risk. The 3- or 5-year cumulativeincidences of HCC were 0-0.8%, 1.5-4.8%, and 8.1-19.9% in the low- (N=7413, 43.6%),medium- (N=6529, 38.4%), and high-risk (N =3044, 17.9%) groups, respectively. Thecut-off value of 50 was associated with a sensitivity of 85.7-100% and a negativepredictive value of 99.3-100%. The cut-off value of 60 resulted in a specificity of56.6-95.8% and a positive predictive value of 6.6-15.7%.ConclusionsThis objective, simple, reliable risk score based on five common parameters accuratelypredicts HCC development, regardless of aetiology and ethnicity, which may help toestablish a risk score-guided HCC surveillance strategy worldwide.

AB - Background & AimsHepatocellular carcinoma (HCC) is the leading cause of death in patients with chronichepatitis. In this international collaboration, we sought to develop a global universal HCCrisk score to predict the HCC development for chronic hepatitis patients.MethodsA total of 17,374 patients, comprising 10,578 treated Asian chronic hepatitis B (CHB)patients, 2510 treated Caucasian CHB patients, 3566 treated hepatitis C virus(HCV)-infected patients (including 2489 patients with cirrhosis achieving a sustainedvirologic response) and 720 non-viral hepatitis (NVH) patients from 11 internationalprospective observational cohorts or randomized controlled trials, were divided into atraining cohort (3688 Asian CHB patients) and 9 validation cohorts with differentaetiologies and ethnicities (N =13,686).ResultsWe developed an HCC risk score, called the aMAP score (ranging from 0 to 100), thatinvolves only age, Male, Albumin-bilirubin and Platelets. This metric performedexcellently in assessing HCC risk not only in patients with hepatitis of differentaetiologies but also in those with different ethnicities (c-index: 0.82-0.87). Cut-off valuesof 50 and 60 were best for discriminating HCC risk. The 3- or 5-year cumulativeincidences of HCC were 0-0.8%, 1.5-4.8%, and 8.1-19.9% in the low- (N=7413, 43.6%),medium- (N=6529, 38.4%), and high-risk (N =3044, 17.9%) groups, respectively. Thecut-off value of 50 was associated with a sensitivity of 85.7-100% and a negativepredictive value of 99.3-100%. The cut-off value of 60 resulted in a specificity of56.6-95.8% and a positive predictive value of 6.6-15.7%.ConclusionsThis objective, simple, reliable risk score based on five common parameters accuratelypredicts HCC development, regardless of aetiology and ethnicity, which may help toestablish a risk score-guided HCC surveillance strategy worldwide.

KW - hepatocellular carcinoma; risk score; hepatitis B virus; hepatitis C virus; non-alcoholic fatty liver disease

U2 - 10.1016/j.jhep.2020.07.025

DO - 10.1016/j.jhep.2020.07.025

M3 - Article

JO - Journal of Hepatology

JF - Journal of Hepatology

SN - 0168-8278

ER -